MMPs (Matrix metalloproteinases) are zinc-dependent endopeptidases.The metzincin superfamily of proteases, to which the MMPs belong, is a larger group of enzymes. MMPs can process a variety of bioactive molecules in addition to breaking down various extracellular matrix proteins. They have been linked to the inactivation of chemokines and cytokines as well as the cleavage of cell surface receptors and the release of apoptotic ligands.Additionally, it is believed that MMPs have a significant impact on the proliferation, migration, differentiation, angiogenesis, apoptosis, and host defense of cells. It is believed that MMP-2 and MMP-9 are crucial for metastasis. MMP-1 is regarded as being significant in osteoarthritis and rheumatoid arthritis. Recent research indicates that MMPs are actively involved in the pathogenesis of aortic aneurysms. The structural proteins of the aortic wall are degraded by excess MMPs. Acute and chronic cardiovascular diseases both exhibit dysregulation of the balance between MMPs and TIMPs.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V73230 | (R)-ND-336 | 2252493-33-5 | (R)-ND-336 is a potent and specific MMP-9 inhibitor (antagonist) with Ki of 19 nM. |
![]() |
V89019 | (S,S)-TAPI-0 | 143457-40-3 | (S,S)-TAPI-0 is a matrix metalloproteinase (MMP) inhibitor that inhibits the growth of Chlamydia trachomatis by inhibiting PDF enzyme activity. |
![]() |
V73262 | 3,3′-Bisdemethylpinoresinol | 340167-81-9 | 3,3′-Bisdemethylpinoresinol, lignin, is a naturally occurring compound with MMP-1 inhibitory activity on UVA-irradiated human dermal fibroblasts. |
![]() |
V105509 | 3-Aminobenzene-1,2-diol | 20734-66-1 | |
![]() |
V102751 | 4-Epianhydrochlortetracycline hydrochloride | 158018-53-2 | |
![]() |
V73256 | Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt | 98992-65-5 | Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt is a MMP12 substrate and may be utilized to detect MMP12 enzyme activity. |
![]() |
V73254 | ADAM8-IN-1 | 2758892-64-5 | ADAM8-IN-1 is a potent ADAM8 inhibitor (antagonist) with IC50 of 73 nM. |
![]() |
V73245 | Aderamastat (FP-025) | 877176-23-3 | Aderamastat (FP-025) is an orally bioactive matrix metalloproteinase 12 (MMP-12) inhibitor. |
![]() |
V87609 | Anti-Human/Mouse denatured collagen type-I Antibody (XL313) | Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse derived IgG1, κ antibody inhibitor against human or mouse denatured collagen type-I. | |
![]() |
V73222 | BPHA | 193807-60-2 | BPHA is a potent orally bioactive inhibitor of MMP-2, MMP-9 and MMP-14 with IC50 of 12 nM, 16 nM and 17 nM respectively. |
![]() |
V89020 | CGS 27023A | 169799-04-6 | CGS 27023A is a non-peptide, orally active MMP inhibitor with Ki values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 and MMP-9, respectively. |
![]() |
V73233 | cis-ACCP | 777075-44-2 | cis-ACCP is an antimetastatic matrix metalloproteinase 2 (MMP-2) selective inhibitor (antagonist) with oral activity. |
![]() |
V85024 | CL-82198 hydrochloride | 1188890-36-9 | |
![]() |
V3665 | CTS-1027 | 193022-04-7 | CTS-1027 is a novel, potent small molecule inhibitor ofMMPs (matrix metalloproteinase)withIC50s of 0.3 nM, 0.5 nM forMMP2,MMP13, respectively, and has > 1,000 fold selectivity over MMP1. |
![]() |
V77131 | CTTHWGFTLC, CYCLIC TFA | CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor of the matrix metalloproteinases MMP-2 and MMP-9. | |
![]() |
V73259 | cyclo(RLsKDK) (BK-1361) | 1975145-82-4 | cyclo(RLsKDK) (BK-1361) is a specific metalloproteinase ADAM8 inhibitor (antagonist) with IC50 of 182 nM. |
![]() |
V51482 | cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) | inhibitor of metalloproteinase ADAM8 | |
![]() |
V79188 | Dnp-PLGLWA-DArg-NH2 TFA | Dnp-PLGLWA-DArg-NH2 TFA is a fluorescent substrate for MMP-1 and MMP-9. | |
![]() |
V73258 | Dnp-PYAYWMR | 135662-06-5 | Dnp-PYAYWMR is a bioactive peptide substrate that selectively targets MMP3. |
![]() |
V73237 | FFAGLDD | 2703745-70-2 | FFAGLDD is an MMP9-selective cleavage peptide for cytosolic delivery of doxorubicin (DOX) and achieves temporally and spatially controlled slow drug delivery and release. |